Objectif EPIGEN test is a ready-to-use tool capable to lead the oncologist to the best Non Smal Cell Lung Cancer treatment, the most common subtype of lung cancer (80% of cases). The standar treatments to combat NSCLC are both chemo- and radiotherapy, but many patients (up to 65%) presents resistance, and currently there is not any tool available for the clinician to predict it. The EPIGEN test will allow the clinician a patient stratification in terms of the patient susceptibility to radio- and chemotherapy, and therefore lead for a personalyzed prescription. The EPIGEN test tecnology is based on the determination of the methylation percentage of the epigenetic biomarker IGFBP-3 in the patient tumor samples. The methylation percentage of IGFBP-3 is determined by using qMS-PCR (quantitative methylation specific polymerase chain) tecnique, a well known and extended biochemistry tecnique. The methylation percentage provided by using the EPIGEN test protocol and reagents in the qMS-PCR tecnique will lead the clinician for the optimal NSCLC treatment, avoiding the possible patient resistance to chemo and radiotharapy, and therefore unnecesary side effects and costly therapies. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineoncologylung cancerengineering and technologymechanical engineeringvehicle engineeringaerospace engineeringsatellite technologymedical and health sciencesbasic medicinephysiologycytologyengineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Appel à propositions H2020-SMEInst-2014-2015 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2015 Régime de financement SME-1 - SME instrument phase 1 Coordinateur IGEN BIOTECH SL Contribution nette de l'UE € 50 000,00 Adresse CALLE GUSTAVO FERNANDEZ BALVUENA 11 28002 MADRID Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Comunidad de Madrid Comunidad de Madrid Madrid Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
